GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » Total Long-Term Assets

ACXP (Acurx Pharmaceuticals) Total Long-Term Assets : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Acurx Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Dec. 2024 was $0.00 Mil.


Acurx Pharmaceuticals Total Long-Term Assets Historical Data

The historical data trend for Acurx Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals Total Long-Term Assets Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Assets
Get a 7-Day Free Trial - - - - -

Acurx Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Acurx Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Acurx Pharmaceuticals Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Acurx Pharmaceuticals Business Description

Traded in Other Exchanges
Address
259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
Executives
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David P Luci director, 10 percent owner, officer: President and CEO
Robert J Deluccia director, 10 percent owner 40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Jack H Dean director C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Carl Sailer director 4 GREENBRIAR LANE, MONTVALE NJ 07645
James J. Donohue director C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305
Thomas L Harrison director
Robert G. Shawah officer: Chief Financial Officer C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004